{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:22:29Z","timestamp":1787026949024,"version":"build-2736575974"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma. Significant unmet need remains for patients with relapsed\/refractory FL after \u22653 lines of prior therapy. While recent advancements have likely improved the survival of patients with FL, most patients will eventually relapse. The treatment of patients with FL after multiple relapses or those with refractory disease has historically led to lower overall response rates (ORR) and shorter progression-free survival (PFS) with each subsequent line of therapy. New treatments with high ORR and durable PFS are needed in this setting, particularly in patients that progress within 2 years of first line chemoimmunotherapy (POD24) and\/or those refractory chemoimmunotherapy. Chimeric antigen receptor T-cell therapies targeting the B-cell antigen CD-19 have shown to be an efficacious treatment option for both heavily pretreated patients and\/or patients with refractory FL, resulting in a high ORR and durable remissions.<\/jats:p>","DOI":"10.3389\/fonc.2024.1384600","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:31:47Z","timestamp":1717547507000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["The treatment of follicular lymphoma with CD19-directed chimeric antigen receptor T-cell therapy"],"prefix":"10.3389","volume":"14","author":[{"given":"Ryan","family":"Jacobs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4265","article-title":"Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation","volume":"99","author":"Biagi","year":"2002","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909","article-title":"The non-hodgkin's lymphoma classification project","volume":"89","year":"1997","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04914-8","article-title":"Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis","volume":"101","author":"Gao","year":"2022","journal-title":"Ann Hematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281421","article-title":"Treatment patterns and outcomes in relapsed\/refractory follicular lymphoma: results from the international SCHOLAR-5 study","volume":"108","author":"Ghione","year":"2023","journal-title":"Haematologica"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15149","article-title":"Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study","volume":"184","author":"Link","year":"2019","journal-title":"Br J haematology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3324\/haematol.2021.278717","article-title":"Prospects in the management of patients with follicular lymphoma beyond first-line therapy","volume":"107","author":"Qualls","year":"2022","journal-title":"Haematologica"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"New Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01467","article-title":"Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell Malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"New Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003959","article-title":"Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting","volume":"5","author":"Ayuk","year":"2021","journal-title":"Blood Adv"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2030164","article-title":"Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy","volume":"384","author":"Chong","year":"2021","journal-title":"New Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000905","article-title":"High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy","volume":"134","author":"Hirayama","year":"2019","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-156120","article-title":"3-year follow-up analysis of ZUMA-5: A phase 2 study of axicabtagene ciloleucel (Axi-cel) in patients with relapsed\/refractory (R\/R) indolent non-hodgkin lymphoma (iNHL)","volume":"140","author":"Neelapu","year":"2022","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174914","article-title":"Axicabtagene ciloleucel (Axi-cel) in patients with relapsed\/refractory indolent non-hodgkin lymphoma: 4-year follow-up from the phase 2 ZUMA-5 trial","volume":"142","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180936","article-title":"Clinical outcomes of patients with relapsed\/refractory follicular lymphoma treated with tisagenlecleucel: phase 2 elara 3-year follow-up","volume":"142","author":"Schuster","year":"2023","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3196_LBA4","article-title":"TRANSCEND FL: PHASE 2 STUDY RESULTS OF LISOCABTAGENE MARALEUCEL (LISO-CEL) IN PATIENTS (PTS) WITH RELAPSED\/REFRACTORY (R\/R) FOLLICULAR LYMPHOMA (FL)","volume":"41","author":"Morschhauser","year":"2023","journal-title":"Hematological Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014375","article-title":"Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed\/refractory follicular lymphoma","volume":"140","author":"Ghione","year":"2022","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-186842","article-title":"An updated comparison of clinical outcomes from 4-year follow-up of zuma-5 (Axicabtagene ciloleucel) and the international scholar-5 external control cohort in relapsed\/refractory follicular lymphoma","volume":"142","author":"Gribben","year":"2023","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.7509","article-title":"Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R\/R) follicular lymphoma (FL)","volume":"41","author":"Jacobson","year":"2023","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008150","article-title":"Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma","volume":"6","author":"Salles","year":"2022","journal-title":"Blood Adv"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.09.022","article-title":"Assessment of healthcare resource utilization and hospitalization costs in patients with relapsed or refractory follicular lymphoma undergoing CAR-T cell therapy with tisagenlecleucel: results from the ELARA study","volume":"29","author":"Fowler","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2023.2289854","article-title":"Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r\/r follicular lymphoma","author":"Dickinson","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-173692","article-title":"Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and\/or Refractory Follicular Lymphoma after \u22652 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study","volume":"142","author":"Schuster","year":"2023","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-178786","article-title":"Matching-adjusted indirect comparison (MAIC) of efficacy and safety of lisocabtagene maraleucel (liso-cel) and mosunetuzumab for the treatment (Tx) of third line or later (3L+) relapsed or refractory (R\/R) follicular lymphoma (FL)","volume":"142","author":"Nastoupil","year":"2023","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-182244","article-title":"Cost effectiveness of mosunetuzumab and CAR-T cell therapy in relapsed\/refractory follicular lymphoma","volume":"142","author":"Lin","year":"2023","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-186548","article-title":"Cost-effectiveness of axicabtagene ciloleucel versus mosunetuzumab in relapsed\/refractory follicular lymphoma in the US","volume":"142","author":"Oluwole","year":"2023","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136440","article-title":"Third generation CD20 targeted CAR T-cell therapy (MB-106) for treatment of patients with relapsed\/refractory B-cell non-hodgkin lymphoma","volume":"136","author":"Shadman","year":"2020","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3163_49","article-title":"HIGH EFFICACY AND FAVORABLE SAFETY OF 3RD GENERATION CD20 CAR-T (MB-106) FOR OUTPATIENT TREATMENT OF FOLLICULAR LYMPHOMA (FL)\u2014RESULTS OF A SINGLE-INSTITUTION TRIAL","volume":"41","author":"Shadman","year":"2023","journal-title":"Hematological Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell Malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005278","article-title":"Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma","volume":"136","author":"Tong","year":"2020","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1182\/blood-2023-189196","article-title":"ALLO-647 for lymphodepletion in the allogeneic CAR T setting: safety experience with ALLO-501\/501A in patients (Pts) with relapsed\/refractory (r\/r) large B-cell and follicular lymphomas","volume":"142","author":"Locke","year":"2023","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01097","article-title":"Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy","volume":"42","author":"Iacoboni","year":"2024","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00033-3","article-title":"Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study","volume":"9","author":"Casulo","year":"2022","journal-title":"Lancet Haematology"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary cancers after chimeric antigen receptor T-cell therapy","author":"Verdun","year":"2024","journal-title":"New Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1384600\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T06:05:07Z","timestamp":1721369107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1384600\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":45,"alternative-id":["10.3389\/fonc.2024.1384600"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1384600","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,5]]},"article-number":"1384600"}}